3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
8
cemiplimab
5
Nivolumab
4
Ipilimumab
4
Blood Specimen Collection
3
lifileucel
2
avelumab
2
aldesleukin
2
Niacinamide
2
Cyclophosphamide
2
toripalimab
1
tislelizumab
1
oxycodone-acetaminophen
1
lenvatinib
1
fludarabine
1
epacadostat
1
encorafenib
1
durvalumab
1
dostarlimab
1
brodalumab
1
binimetinib
1
atezolizumab
1
Vitamin A
1
Surgical Procedures, Operative
1
Sunscreening Agents
1
Standard of Care
1
Specimen Handling
1
Resistance Training
1
Radiotherapy
1
Niacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
MAPRE1 protein, human
×
90 days
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled